Presage Biosciences, a cancer biotechnology company pioneering the use of intratumoral microdosing for Phase 0 investigation of early development candidates, announced that it has closed a Series D financing led by pharmaceutical companies Takeda and Celgene.
Presage Biosciences is an oncology company pioneering a new drug development approach to assess novel therapeutics and combinations directly in living tumors with its patented CIVO™ intratumoral microdosing platform. The CIVO device is intended to enable simultaneous assessment of responses to multiple drugs or drug combinations directly in a single tumor while still in a patient’s body.
Presage also partners with oncology-focused pharmaceutical companies through strategic alliances to provide preclinical data to discover effective drug combinations. Presage is privately held and based in Seattle, USA.
Dave Johnson, Chairman of the Board, said:
“We are thrilled to have closed this financing with long-time Presage strategic partners, Takeda and Celgene. This $6 million investment brings the total equity raised by Presage to $26 million and comes at an important time for Presage as we aim to broaden the use of the CIVO™ platform in clinical intratumoral microdosing studies with a range of biopharma partners.”